Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol®) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cance. Results of a dose escalation study

Lung Cancer

Volumn 32, Issue 2, 2001, Pages 163-171

  Willner, Jochen ^a   Schmidt, Michael ^a   Kirschner, Joachim ^a   Lang, Susanne ^b   Borgmeier, Astrid ^b   Huber, Rudolf M ^b   Flentje, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

3D conformal radiotherapy; Dose escalation study; Non small cell lung cancer; Paclitaxel; Radiochemotherapy; Sequential chemo radiochemotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; ESOPHAGITIS; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG HYPERSENSITIVITY; ESOPHAGITIS; HUMANS; LEUKOPENIA; LIFE TABLES; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; NAUSEA; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIOTHERAPY, CONFORMAL; REMISSION INDUCTION; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

EID: 0035038575     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00216-6     Document Type: Article

References (24)

1. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer
2. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study
3. Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer
4. Concurrent paclitaxel and radiotherapy - treatment feasibility studies
5. Phase II-studie zur therapieintensivierung beim lokal fortgeschrittenen nichtkleinzelligen bronchialkarzinom
6. Paclitaxel as a radiation sensitizer in non-small cell lung cancer
7. Kombinationswirkung von paclitaxel und ionisierender strahlung. experimentelle daten aus in-vitro- und in-vivo-modellen
8. Taxol: a novel radiation sensitizer
9. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations
10. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer
11. A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer
12. Paclitaxel and radiotherapy in the treatment of advanced non-small cell lung cancer
13. Lung fibrosis induced by paclitaxel
14. Weekly paclitaxel and Carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced nonsmall cell lung cancer (NSCLC): three year follow-up
15. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
16. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
17. Phase I/II trial of paclitaxel (TAX) cisplatin (DDP) and radiation therapy for stage III non-small cell lung cancer
18. Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
19. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer
20. The biological basis for conformal three-dimensional radiation therapy
21. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group
22. Dose escalation for non-small cell lung cancer using conformal radiation therapy
23. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial